- /
- Supported exchanges
- / US
- / CLLS.NASDAQ
Cellectis SA (CLLS NASDAQ) stock market data APIs
Cellectis SA Financial Data Overview
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Cellectis SA (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Cellectis SA data using free add-ons & libraries
Get Cellectis SA Fundamental Data
Cellectis SA Fundamental data includes:
- Net Revenue: 32 098 K
- EBITDA: -112 128 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-11-12
- EPS/Forecast: -0.21
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cellectis SA News
New
European Equities Traded in the US as American Depositary Receipts Kick Off Week Lower in Monday Trading
European equities traded in the US as American depositary receipts kicked off the week tracking lowe Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news ...
Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene Editing ...
This article first appeared on GuruFocus. Release Date: November 13, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Celle...
Cellectis GAAP EPS of -$1.00, revenue of $19.89M
* Cellectis press release [https://seekingalpha.com/filing/310291331] (CLLS [https://seekingalpha.com/symbol/CLLS]): 9M GAAP EPS of -$1.00. * Revenue of $19.89M. MORE ON CELLECTIS * Cellectis ...
European Equities Traded in the US as American Depositary Receipts Rise Marginally in Friday Trading
European equities traded in the US as American depositary receipts were marginally higher late Frida Keep reading this article with Yahoo Finance Plus Silver Upgrade to Silver Silver Premium news ...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.